ES2120402T3 - Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar. - Google Patents

Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar.

Info

Publication number
ES2120402T3
ES2120402T3 ES88310942T ES88310942T ES2120402T3 ES 2120402 T3 ES2120402 T3 ES 2120402T3 ES 88310942 T ES88310942 T ES 88310942T ES 88310942 T ES88310942 T ES 88310942T ES 2120402 T3 ES2120402 T3 ES 2120402T3
Authority
ES
Spain
Prior art keywords
salt
lipase
biliar
procedures
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88310942T
Other languages
English (en)
Inventor
Jordan J N Tang
Chi-Sun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of ES2120402T3 publication Critical patent/ES2120402T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01003—Triacylglycerol lipase (3.1.1.3)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/1203—Addition of, or treatment with, enzymes or microorganisms other than lactobacteriaceae
    • A23C9/1216—Other enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S426/00—Food or edible material: processes, compositions, and products
    • Y10S426/801—Pediatric

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Steroid Compounds (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSICIONES DE DIETAS, ESPECIALMENTE FORMULAS PARA NIÑOS A BASE DE LECHE DE VACA, SE FORTALECEN CON LIPASA ACTIVADA CON SAL DE BILIS. SE PROPORCIONAN METODOS PARA ALIMENTAR RECIEN NACIDOS Y NIÑOS PREMATUROS, QUE INCLUYEN LA ADMINISTRACION DE LIPASA ACTIVADA POR SAL DE BILIS PARA AUMENTAR LA DIGESTION DE LA GRASA Y CON ELLO LA VELOCIDAD DE CRECIMIENTO.. DE MODO SIMILAR, SE PROPORCIONA UN METODO PARA TRATAR SUJETOS CON INADECUADA PRODUCCION DE ENZIMA PANCREATICO, POR ADMINISTRACION DE LIPASA ACTIVADA CON SAL DE BILIS, JUNTO CON INGESTION DE GRASAS.
ES88310942T 1987-11-19 1988-11-18 Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar. Expired - Lifetime ES2120402T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/122,410 US4944944A (en) 1987-11-19 1987-11-19 Dietary compositions and methods using bile salt-activated lipase

Publications (1)

Publication Number Publication Date
ES2120402T3 true ES2120402T3 (es) 1998-11-01

Family

ID=22402581

Family Applications (2)

Application Number Title Priority Date Filing Date
ES88310942T Expired - Lifetime ES2120402T3 (es) 1987-11-19 1988-11-18 Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar.
ES93203480T Expired - Lifetime ES2152941T3 (es) 1987-11-19 1988-11-18 Utilizacion de lipasa activada de sal biliar como suplemento dietetico.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES93203480T Expired - Lifetime ES2152941T3 (es) 1987-11-19 1988-11-18 Utilizacion de lipasa activada de sal biliar como suplemento dietetico.

Country Status (7)

Country Link
US (1) US4944944A (es)
EP (2) EP0317355B1 (es)
JP (2) JP2592939B2 (es)
AT (2) ATE167982T1 (es)
DE (2) DE3856214T2 (es)
ES (2) ES2120402T3 (es)
GR (1) GR3035093T3 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US5200183A (en) * 1987-11-19 1993-04-06 Oklahoma Medical Research Foundation Recombinant bile salt activated lipases
US5000975A (en) * 1988-12-29 1991-03-19 American Home Products Corporation Randomized palm oil fat composition for infant formulas
US5008120A (en) * 1989-07-21 1991-04-16 Snow Brand Milk Products Co., Ltd. Method of preparing iron-fortified beverage
US5173408A (en) * 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
JP2808166B2 (ja) * 1990-04-26 1998-10-08 雪印乳業株式会社 鉄強化飲料の製造方法
US5186961A (en) * 1991-03-15 1993-02-16 North Carolina State University Method and composition for maintaining animals on a keratin-containing diet
US5169666A (en) * 1991-11-14 1992-12-08 The United States Of America As Represented By The Secretary Of Agriculture Preparation of simulated human milk protein by low temperature microfiltration
US5902617A (en) * 1992-05-19 1999-05-11 Pabst; Patrea L. Enzyme supplemented baby formula
HRP930935A2 (en) * 1992-06-11 1994-12-31 Astra Ab New dna sequences
GB9212511D0 (en) * 1992-06-12 1992-07-22 Cortecs Ltd Pharmaceutical compositions
US5460812A (en) * 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) * 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
IS4130A (is) * 1993-03-01 1994-09-02 Ab Astra Ný fjölpeptíð
US5821226A (en) * 1994-12-01 1998-10-13 Oklahoma Medical Research Foundation BAL C-tail drug delivery molecules
US5681819A (en) * 1994-12-01 1997-10-28 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US5696087A (en) * 1994-12-01 1997-12-09 Oklahoma Medical Research Foundation Method and compositions for reducing cholesterol absorption
US6342218B1 (en) 1997-02-14 2002-01-29 Oklahoma Medical Research Foundation Method for treatment of SLE
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US7008776B1 (en) * 1996-12-06 2006-03-07 Aventis Pharmaceuticals Inc. Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
US6395530B1 (en) * 1996-12-06 2002-05-28 Aventis Pharmaceuticals Inc. LLG polypeptides of the triacylglycerol lipase family, and compositions and methods for their use in enzymatic hydrolysis, and protein and gene therapies
ES2331442T3 (es) 1998-03-23 2010-01-04 General Mills, Inc. Encapsulacion de componentes en productos comestibles.
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
ATE413889T1 (de) * 1998-06-05 2008-11-15 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
US6399090B1 (en) * 1998-06-05 2002-06-04 Insotech Ltd. Insulin supplemented infant formula
WO2001089553A1 (en) * 1999-05-19 2001-11-29 Barnes Jewish Hospital Enhanced triglyceride digestion in a deficiency of bile salts
EP1059041A1 (en) * 1999-06-07 2000-12-13 Universiteit Gent The combined use of triglycerides containing medium chain fatty acids and exogenous lipolytic enzymes as feed supplements
US6500463B1 (en) 1999-10-01 2002-12-31 General Mills, Inc. Encapsulation of sensitive components into a matrix to obtain discrete shelf-stable particles
US6468568B1 (en) 2000-06-16 2002-10-22 General Mills, Inc. Oligosaccharide encapsulated mineral and vitamin ingredients
US6436453B1 (en) 2000-06-16 2002-08-20 General Mills, Inc. Production of oil encapsulated minerals and vitamins in a glassy matrix
US6558718B1 (en) 2000-06-19 2003-05-06 General Mills, Inc. Nutrient clusters for food products and methods of preparation
EP1539222A1 (en) * 2002-07-02 2005-06-15 The Regents Of The University Of California Treatment for eye disorder
US7431986B2 (en) 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
CA3007908A1 (en) 2003-03-07 2005-04-14 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US7803413B2 (en) 2005-10-31 2010-09-28 General Mills Ip Holdings Ii, Llc. Encapsulation of readily oxidizable components
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
EP1987142A4 (en) 2006-02-02 2009-07-15 Verenium Corp ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS
AR059692A1 (es) * 2007-03-01 2008-04-23 Adriana Fernandez Alimento de alto contenido calorico y de facil digestion
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8153391B2 (en) 2008-08-29 2012-04-10 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
US8357503B2 (en) 2008-08-29 2013-01-22 Bunge Oils, Inc. Hydrolases, nucleic acids encoding them and methods for making and using them
EP2629789A1 (en) * 2010-10-21 2013-08-28 Swedish Orphan Biovitrum AB (Publ) Method to increase the absorption of unsaturated fatty acids by human infants
WO2012052060A1 (en) 2010-10-21 2012-04-26 Swedish Orphan Biovitrum Ab (Publ) Method to increase the growth velocity of human infants
AU2013221572B2 (en) 2012-02-17 2017-12-21 Alcresta Therapeutics, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
GB201501081D0 (en) 2015-01-22 2015-03-11 Cilian Ag Use of enzymes with a wide pH activity range as medicaments for promoting digestion
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
ES2957891T3 (es) 2016-03-24 2024-01-29 Elgan Pharma Ltd Uso de insulina para promover el vaciamiento gástrico
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA662815A (en) * 1963-05-07 G. Farnham Merle Treatment for "scours" in mammals
US3256150A (en) * 1964-04-20 1966-06-14 Dairyland Food Lab Method for treating malabsorption syndrome
US3991180A (en) * 1972-03-06 1976-11-09 Rohm And Haas Company Stabilization of internally administered pancreatic lipase
JPS5017559B2 (es) * 1972-09-20 1975-06-21
GB1509866A (en) * 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
DE2638089C2 (de) * 1976-08-24 1985-04-25 Degussa Ag, 6000 Frankfurt Lipase-Präparate mit verbesserter Wirkung
GB1571877A (en) * 1978-04-24 1980-07-23 Meito Sangyo Kk Microbial lipase and its preparation
JPS6047858B2 (ja) * 1978-09-20 1985-10-24 田村 輝 温浴用水製造装置
DE2923279C2 (de) * 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
ATE76561T1 (de) * 1985-01-09 1992-06-15 Genencor Inc Ueberfuehrung von exogenen stoffen in kaesebruch.
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase

Also Published As

Publication number Publication date
JP2592939B2 (ja) 1997-03-19
JPH01231848A (ja) 1989-09-18
US4944944A (en) 1990-07-31
ATE167982T1 (de) 1998-07-15
HK1023031A1 (en) 2000-08-25
HK1012213A1 (en) 1999-07-30
DE3856435D1 (de) 2000-11-30
EP0317355B1 (en) 1998-07-08
DE3856214T2 (de) 1998-12-17
EP0605913B1 (en) 2000-10-25
EP0317355A3 (en) 1991-07-17
GR3035093T3 (en) 2001-03-30
EP0605913A1 (en) 1994-07-13
ES2152941T3 (es) 2001-02-16
DE3856435T2 (de) 2001-03-29
EP0317355A2 (en) 1989-05-24
ATE197127T1 (de) 2000-11-15
JPH06315347A (ja) 1994-11-15
DE3856214D1 (de) 1998-08-13

Similar Documents

Publication Publication Date Title
ES2120402T3 (es) Composiciones dieteticas y procedimientos de utilizacion de lipasa activada por sal biliar.
US6699496B1 (en) Enzyme in a dosage form for oral use in mammals, enzyme-containing food material and method for administering the enzyme in a dosage form
EP0347056B1 (en) Essential fatty acid compositions
AU628662B2 (en) Dietary supplement and method of minimizing effects of infection through diet
GB9519661D0 (en) Fatty acid treatment
ES2185744T3 (es) Composicion nutritiva.
PL338219A1 (en) Therapeutic and dietary compositions containing necessary unsaturated fatty acids and biologically active disulphides
DE69028712D1 (de) Zusammensetzung zur behandlung entzündlicher darmerkrankungen
ATE88631T1 (de) Zusatznahrung bzw. therapie fuer personen mit risiko oder in behandlung fuer arteriosklerotische vaskulaere, kardiovaskulaere und/oder thrombotische erkrankungen.
MX9605144A (es) Producto nutritivo para el tratamiento de la colitis ulcerativa y uso del mismo.
Sarles et al. Alcoholic pancreatitis
EP0315113A3 (en) Inner esters of gangliosides with analgesic-antiinflammatory activity
ATE238805T1 (de) Multifunktionelle formulierung für fettabsorbierung und zur senkung des cholesterolgehaltes im blut, welche chitosan und nicotinsäure enthält
MY131357A (en) Fatty acid treatment
EP0409559A3 (en) Pharmaceutical and dietary uses of fatty acids
AU1489688A (en) Omega-3 fatty acids in traumatic injury treatment
Bates Racially determined abnormal essential fatty acid and prostaglandin metabolism and food allergies linked to autoimmune, inflammatory, and psychiatric disorders among coastal British Columbia indians
EP0187653A3 (en) Pharmaceutical compositions replacing the bile and aidinpharmaceutical compositions replacing the bile and aiding the digestion of fats, and process for their preparatig the digestion of fats, and process for their preparation on
Böhles et al. Deficiencies of essential fatty acids and vitamin E in cystic fibrosis
de Leon et al. The effect of dihydroxydibutylether on bile lipid composition in patients with gallstones

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 317355

Country of ref document: ES